|
Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. |
|
|
Honoraria - Mylan; Puma Biotechnology; Samsung Bioepis |
Consulting or Advisory Role - Napo Pharmaceuticals |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Sermonix Pharmaceuticals (Inst) |
|
|
Consulting or Advisory Role - bioTheranostics; Daiichi Sankyo/Astra Zeneca; Foundation Medicine; Genentech; Genentech/Roche (Inst); Immunomedics; Immunomedics (Inst); Innocrin Pharma (Inst); Merck; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Philips Healthcare; Puma Biotechnology; Radius Health; Radius Health (Inst); Sanofi; Spectrum Pharmaceuticals |
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst) |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Leuko (I); MedSIR; Nektar |
Honoraria - Celgene; Daiichi Sankyo; Eisai; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung |
Consulting or Advisory Role - AstraZeneca; Athenex; Bioasis; Bioinvent; Boehringer Ingelheim; Celgene; Cellestia Biotech; Clovis Oncology; Daiichi Sankyo; Ellipses Pharma; ERYTECH Pharma; GEMoaB; Gilead Sciences; GlaxoSmithKline; HiberCell; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Reveal Genomics; Roche; Seagen; SERVIER; Zymeworks |
Research Funding - ARIAD (Inst); AstraZeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst) |
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A. |
Travel, Accommodations, Expenses - Daiichi Sankyo; Eisai; Gilead Sciences; Novartis; Pfizer; Roche |
|
|
|
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Merck; Novartis; Pfizer; Puma Biotechnology; Roche |
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation; Novartis (Inst); Oncogenex (Inst); Roche (Inst) |
|
|
Honoraria - Amgen; AstraZeneca Canada; Eisai; Gilead Sciences; Lilly; MSD; Novartis |
Consulting or Advisory Role - 4D Pharma; Amgen; AstraZeneca; Daiichi Sankyo; Eisai; Immunomedics; Lilly; MSD; Novartis; Pfizer; Roche |
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Gilead Sciences; MSD; Novartis; Pfizer; Roche |
|
|
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; Eisai Europe; Gilead Sciences; Lilly; MSD Oncology; Pfizer; Pierre Fabre; Pierre Fabre; Roche; Sandoz-Novartis; Seagen |
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Lilly; MSD Oncology; Novartis; Pfizer; Roche |
|
|
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Lilly; Novartis; Pfizer; Roche |
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Lilly; Pfizer |
Travel, Accommodations, Expenses - Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; AstraZeneca; Biotheranostics; BluePrint Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Intellisphere; Jounce therapeutics; Lilly; Novartis; Pfizer; Sanofi; Seagen; Sun Pharma Advanced Research Company; Synthon; Taiho Oncology |
Research Funding - ADC Therapeutics (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); Pfizer (Inst); Puma Biotechnology (Inst); VelosBio/Merck (Inst); Zymeworks (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Intellisphere; Jounce Therapeutics; Pfizer; Taiho Pharmaceutical |
|
|
Employment - Gilead Sciences |
Stock and Other Ownership Interests - Gilead Sciences |
|
|
Employment - Gilead Sciences |
Stock and Other Ownership Interests - Gilead Sciences |
|
|
Employment - Gilead Sciences |
Stock and Other Ownership Interests - Gilead Sciences |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Athenex; BeyondSpring Pharmaceuticals; Blueprint Medicines; Bristol-Myers Squibb; Certara Inc; Chugai Pharma; CytomX Therapeutics; Daiichi Sankyo; Eisai; Ellipses Pharma; G1 Therapeutics; Genentech; Immunomedics/Gilead; Infinity Pharmaceuticals; Kyowa Hakko Kirin; Lilly; Merck; Mersana; NanoString Technologies; Nektar; Novartis; Odonate Therapeutics; OncoPep; OncoSec; OncXerna Therapeutics; Paxman; Pfizer; Puma Biotechnology; Reveal Genomics; Samsung Bioepis; Sanofi; Seagen; Zentalis; Zymeworks |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Nektar (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst) |